Concepedia

Publication | Open Access

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial

DOIFull Paper Access

41

Citations

31

References

2024

Year

Christoph Wanner, Masaomi Nangaku, Bettina J. Kraus, Bernard Zinman, Michaela Mattheus, Stefan Hantel, Martin Schumacher, Kristin Ohneberg, Claudia Schmoor, Silvio E. Inzucchi
Nephrology Dialysis Transplantation

Abstract

Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.

References

YearCitations

Page 1